Literature DB >> 20951118

Sclerostin-erbB-3 interactions: modulation of erbB-3 activity by sclerostin.

Theodore A Craig1, Rajiv Kumar.   

Abstract

To gain insights into the mechanism of action of sclerostin, a protein that regulates bone mass, we performed yeast two-hybrid analyses using human SOST (sclerostin) cDNA cloned into pGBKT7 DNA-binding domain vector as a bait, and a normalized, high-complexity, universal cDNA library in a GAL4 activating domain vector. We identified an interaction between sclerostin and the carboxyl-terminal portion of the receptor tyrosine-protein kinase erbB-3. To determine the biological relevance of this interaction, we treated MC3T3-E1 mouse osteoblast cells transfected with either a SOST expression plasmid or a control vector, with recombinant heregulin/neuregulin. Phospho-p44/42 (Thr202/Tyr204) MAPK was assessed in heregulin/neuregulin treated cells. We observed an increase in phospho-p44/42 (Thr202/Tyr204) MAPK concentrations in SOST transfected cells but not in cells transfected with a control vector, thus demonstrating a modulatory effect of sclerostin on heregulin/neuregulin signaling in osteoblasts. The data demonstrate that sclerostin functions in part, by modulating the activity of erbB-3.
Copyright © 2010 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20951118      PMCID: PMC2992958          DOI: 10.1016/j.bbrc.2010.10.048

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  26 in total

1.  High bone density due to a mutation in LDL-receptor-related protein 5.

Authors:  Randall D Little; Robert R Recker; Mark L Johnson
Journal:  N Engl J Med       Date:  2002-09-19       Impact factor: 91.245

2.  Convergence of the BMP and EGF signaling pathways on Smad1 in the regulation of chondrogenesis.

Authors:  K Nonaka; L Shum; I Takahashi; K Takahashi; T Ikura; R Dashner; G H Nuckolls; H C Slavkin
Journal:  Int J Dev Biol       Date:  1999-11       Impact factor: 2.203

3.  A mutation in the LDL receptor-related protein 5 gene results in the autosomal dominant high-bone-mass trait.

Authors:  Randall D Little; John P Carulli; Richard G Del Mastro; Josée Dupuis; Mark Osborne; Colleen Folz; Susan P Manning; Pamela M Swain; Shan-Chuan Zhao; Brenda Eustace; Michelle M Lappe; Lia Spitzer; Susan Zweier; Karen Braunschweiger; Youssef Benchekroun; Xintong Hu; Ronald Adair; Linda Chee; Michael G FitzGerald; Craig Tulig; Anthony Caruso; Nia Tzellas; Alicia Bawa; Barbara Franklin; Shannon McGuire; Xavier Nogues; Gordon Gong; Kristina M Allen; Anthony Anisowicz; Arturo J Morales; Peter T Lomedico; Susan M Recker; Paul Van Eerdewegh; Robert R Recker; Mark L Johnson
Journal:  Am J Hum Genet       Date:  2001-12-03       Impact factor: 11.025

4.  High bone density due to a mutation in LDL-receptor-related protein 5.

Authors:  Lynn M Boyden; Junhao Mao; Joseph Belsky; Lyle Mitzner; Anita Farhi; Mary A Mitnick; Dianqing Wu; Karl Insogna; Richard P Lifton
Journal:  N Engl J Med       Date:  2002-05-16       Impact factor: 91.245

5.  Expression of epidermal growth factor in transgenic mice causes growth retardation.

Authors:  S Y Chan; R W Wong
Journal:  J Biol Chem       Date:  2000-12-08       Impact factor: 5.157

6.  Formation of the sphenomandibular ligament by Meckel's cartilage in the mouse: possible involvement of epidermal growth factor as revealed by studies in vivo and in vitro.

Authors:  K Ishizeki; N Takahashi; T Nawa
Journal:  Cell Tissue Res       Date:  2001-04       Impact factor: 5.249

7.  Bone dysplasia sclerosteosis results from loss of the SOST gene product, a novel cystine knot-containing protein.

Authors:  M E Brunkow; J C Gardner; J Van Ness; B W Paeper; B R Kovacevich; S Proll; J E Skonier; L Zhao; P J Sabo; Y Fu; R S Alisch; L Gillett; T Colbert; P Tacconi; D Galas; H Hamersma; P Beighton; J Mulligan
Journal:  Am J Hum Genet       Date:  2001-02-09       Impact factor: 11.025

Review 8.  Transgenic and knock-out mice for deciphering the roles of EGFR ligands.

Authors:  R W C Wong
Journal:  Cell Mol Life Sci       Date:  2003-01       Impact factor: 9.261

9.  A 52-kb deletion in the SOST-MEOX1 intergenic region on 17q12-q21 is associated with van Buchem disease in the Dutch population.

Authors:  Karen Staehling-Hampton; Sean Proll; Bryan W Paeper; Lei Zhao; Patrick Charmley; Analisa Brown; Jessica C Gardner; David Galas; Randall C Schatzman; Peter Beighton; Socrates Papapoulos; Herman Hamersma; Mary E Brunkow
Journal:  Am J Med Genet       Date:  2002-06-15

10.  Sclerostin binds and regulates the activity of cysteine-rich protein 61.

Authors:  Theodore A Craig; Resham Bhattacharya; Debabrata Mukhopadhyay; Rajiv Kumar
Journal:  Biochem Biophys Res Commun       Date:  2009-12-31       Impact factor: 3.575

View more
  8 in total

1.  Enhanced prostacyclin formation and Wnt signaling in sclerostin deficient osteocytes and bone.

Authors:  Zachary C Ryan; Theodore A Craig; Jeffrey L Salisbury; Lomeli R Carpio; Meghan McGee-Lawrence; Jennifer J Westendorf; Rajiv Kumar
Journal:  Biochem Biophys Res Commun       Date:  2014-04-26       Impact factor: 3.575

2.  The sclerostin-bone protein interactome.

Authors:  Hemamalini Devarajan-Ketha; Theodore A Craig; Benjamin J Madden; H Robert Bergen; Rajiv Kumar
Journal:  Biochem Biophys Res Commun       Date:  2011-12-22       Impact factor: 3.575

3.  Anabolic and catabolic regimens of human parathyroid hormone 1-34 elicit bone- and envelope-specific attenuation of skeletal effects in Sost-deficient mice.

Authors:  Alexander G Robling; Rajendra Kedlaya; Shana N Ellis; Paul J Childress; Joseph P Bidwell; Teresita Bellido; Charles H Turner
Journal:  Endocrinology       Date:  2011-06-07       Impact factor: 4.736

4.  Determination of serum and plasma sclerostin concentrations by enzyme-linked immunoassays.

Authors:  Melissa McNulty; Ravinder J Singh; Xujian Li; Eric J Bergstralh; Rajiv Kumar
Journal:  J Clin Endocrinol Metab       Date:  2011-05-04       Impact factor: 5.958

5.  Sclerostin alters serum vitamin D metabolite and fibroblast growth factor 23 concentrations and the urinary excretion of calcium.

Authors:  Zachary C Ryan; Hemamalini Ketha; Melissa S McNulty; Meghan McGee-Lawrence; Theodore A Craig; Joseph P Grande; Jennifer J Westendorf; Ravinder J Singh; Rajiv Kumar
Journal:  Proc Natl Acad Sci U S A       Date:  2013-03-25       Impact factor: 11.205

Review 6.  Reduced renal calcium excretion in the absence of sclerostin expression: evidence for a novel calcium-regulating bone kidney axis.

Authors:  Rajiv Kumar; Volker Vallon
Journal:  J Am Soc Nephrol       Date:  2014-05-29       Impact factor: 10.121

7.  Sclerostin inhibition reverses skeletal fragility in an Lrp5-deficient mouse model of OPPG syndrome.

Authors:  Rajendra Kedlaya; Shreya Veera; Daniel J Horan; Rachel E Moss; Ugur M Ayturk; Christina M Jacobsen; Margot E Bowen; Chris Paszty; Matthew L Warman; Alexander G Robling
Journal:  Sci Transl Med       Date:  2013-11-13       Impact factor: 17.956

8.  Sclerostin inhibits osteoblast differentiation without affecting BMP2/SMAD1/5 or Wnt3a/β-catenin signaling but through activation of platelet-derived growth factor receptor signaling in vitro.

Authors:  Cyril Thouverey; Joseph Caverzasio
Journal:  Bonekey Rep       Date:  2015-11-04
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.